The effects of human immunodeficiency virus (HIV) protease inhibitors (PI) on the accumulation of the fluorescent bile salt analogue cholyl-glycylamido-fluorescein (CGamF) were determined in organic anion transporting polypeptide (OATP)-1B1 and -1B3-expressing Chinese hamster ovary (CHO) cells. In addition, interaction studies in Caco-2 monolayers, known only to express the OATP2B1 isoform, were conducted using the established OATP substrate estrone 3-sulfate (E3S), since no CGamF accumulation was observed in Caco-2 monolayers. CGamF appeared an excellent substrate for the OATP1B subfamily, with net accumulation clearance values of 7.8 and 142 microl min(-1) mg(-1) protein in OATP1B1 and OATP1B3-transfected cells, respectively. K(i)-values reflecting inhibition of CGamF accumulation by HIV PI correlated well between OATP1B1 and OATP1B3-expressing cells. Lopinavir was the most potent inhibitor (K(i) = 0.5-1.4 microM) of OATP1B-mediated CGamF accumulation compared with atazanavir, darunavir, ritonavir, and saquinavir (K(i) between 1.4 and 3.3 microM). Inhibitory profiles towards OATP2B1-mediated E3S accumulation were different with only indinavir, saquinavir, and ritonavir showing substantial effects. In conclusion, OATP1B3 appears to be a major transport mechanism mediating sodium-independent CGamF accumulation in human liver, and CGamF could be used as a probe substrate for in vitro drug interaction studies. The remarkably potent inhibition of OATP1B1 by lopinavir may explain some clinically relevant drug interactions between lopinavir and OATP1B substrates such as fexofenadine. 
Organic anion transporting polypeptides (OATP/Oatp, Human/Rat, SLCO/Slco) belong to a growing superfamily of transporters that mediate cellular accumulation of structurally diverse amphiphilic organic solutes . Eleven human OATP isoforms and 14 rat Oatp isoforms have thus far been identified. OATP1B1, OATP1B3 and OATP2B1 are the three human OATPs that are now considered to play a crucial role in hepatic uptake of exogenous and endogenous compounds at the liver sinusoidal membrane domain. OATP1B1 and 1B3 are liver-specific, whereas OATP2B1 displays wide tissue distribution (Annaert et al., 2007) .
Many drugs have been identified as OATP substrates and clinical drug interactions that can be attributed to the OATP inhibition have been observed (Konig et al., 2006; Hagenbuch and Gui, 2008) . For example, heart transplant patients receiving cyclosporine and rosuvastatin showed a sevenfold increase in rosuvastatin AUC as compared to historical controls (Simonson et al., 2004) .
On the other hand, rosuvastatin exhibits no drug interaction when coadministered with the potent CYP3A4 inhibitor ketoconazole (Cooper et al., 2003) . Rosuvastatin is not transported by the canalicular transporters MDR1 (ABCB1) or MRP2 (ABCC2) (Huang et al., 2006) , however interference with its OATP-mediated hepatic uptake was found to contribute significantly to the marked interaction with cyclosporin. Apart from OATP-mediated drug interactions, interindividual variability in genes encoding OATP transporters can also result in marked interindividual differences in pharmacokinetics; the impact of OATP1B1 polymorphisms has been extensively documented. For example, a single-nucleotide polymorphism (c.521T>C, P.Val174Ala) in the SLCO1B1 gene encoding OATP1B1 decreases the ability of OATP1B1 to transport simvastatin, resulting in markedly increased plasma concentrations of simvastatin and an enhanced risk of simvastatin-induced myopathy (Link et al., 2008) . The SLCO1B1 polymorphism also has implications regarding the hepatic uptake of bile acids in vivo in human (Xiang et al., 2009) .
These examples illustrate that mechanisms underlying hepatic drug interactions frequently extend beyond the classical involvement of P450-mediated drug metabolism (DuBuske, 2005; Endres et al., 2006 ). In addition, since endogenous compounds such as bile salts rely on hepatic transporters to maintain normal hepatic physiology (e.g., bile flow), drugs that inhibit the function of key transporters may also cause important disturbances of endogenous substance elimination via the hepatobiliary system. The use of probe substrates and inhibitors to determine the relative importance of individual hepatic transporters has advanced the value of uptake data obtained using hepatocytes in drug discovery (Soars et al., 2007) . However, as discussed by Wang et al. (Wang et al., 2008) , although the use of selective inhibitors of efflux transporters can provide useful mechanistic information on drug interactions involving efflux transporters, the potential cross-reaction of inhibitors with multiple transporters makes it difficult to discern the role of individual transporters in drug transport. For instance, MK 571 has been considered a specific inhibitor for MRP2 (Gekeler et al., 1995) , but some studies have indicated that it can also inhibit uptake transporters OATP1B1, 1B3 and 2B1 (Yamazaki et al., 2005; Letschert et al., 2006) . Elacridar was originally synthesized to be a selective inhibitor for MDR1 (Wallstab et al., 1999) , but was found to also potently inhibit BCRP ( ABCG2) (de Bruin et al., 1999) .
It follows that continuing efforts are required to identify and thoroughly profile new transporter probe substrates and inhibitors. In this context, we recently reported on the characterization of the hepatic disposition of the bile salt analog cholyl-glycylamido-fluorescein (CGamF) in animal and human hepatocytes (Ye et al., 2008; Ye et al., 2009) . CGamF was synthesized by conjugation of 5-aminofluorescein with the carboxylic group of the natural bile acid cholylglycine yielding a fluorescent bile salt analogue (Holzinger et al., 1998) . The utility of CGamF as a convenient fluorescent probe simulating bile salt transport in various in vitro and in vivo models of different species has been demonstrated previously (Maglova et al., 1995; Bravo et al., 1998; Holzinger et al., 1998; Mita et al., 2006) . Mita et al. (2006) showed that CGamF as well as other fluorescent bile salt analogues were transported across LLC-PK1 cells co-expressing NTCP (SLC10A1) and BSEP (ABCB11), albeit at a substantially lower rate than the natural bile salt taurocholate. In rat and human hepatocytes, we demonstrated that CGamF is mainly accumulated by sodium-independent mechanisms that are sensitive to the OATP inhibitor rifampicin (Ye et al., 2008; Ye et al., 2009 ).
Coincubation of CGamF with digoxin (to inhibit OATP1B3 in human and Oatp1a4 in rat (Annaert et al., 2007) ), caused some inhibition but less than following coincubation with rifampicin in rat and human, indicating that at least OATP1B3/Oatp1a4 is involved in the hepatic uptake of CGamF in the human/rat liver. However, while these data strongly support a pivotal role of OATPs in CGamF accumulation, the relative contribution of the three OATP isoforms that are expressed in the basolateral membrane of hepatocytes (OATP1B1, OATP1B3 and OATP2B1) are not known.
A range of expression systems have been utilized to investigate the substrate specificity of OATPs, including Xenopus laevis oocytes injected with complementary RNA (Hagenbuch et al., 1996) and stable transfections of OATPs in cell lines such as Chinese Hamster Ovary (CHO) cells (Treiber et al., 2007; Gui et al., 2008) . In addition, the well known Caco-2 cell line shows substantial expression of OATP2Bl in the apical membrane, where it contributes predominantly to the accumulation of E3S, thus making Caco-2 cells an attractive in vitro tool for assessing OATP2B1-mediated drug-drug interactions (Sai et al., 2006) .
In the present study, we expanded our previous in vitro data obtained in animal and human hepatocytes by conducting CGamF transport and interaction experiments in OATP1B1 and 1B3 transfected CHO cells. In addition, E3S was used as model substrate for the OATP2B1-mediated interaction with HIV PI since CGamF did not accumulate in Caco-2 cells. were purchased from Lonza Verviers SPRL (Verviers, Belgium). L-proline, sodium butyrate, estrone-3-sulfate, digoxin, rifampicin, rifamycin SV, bromsulphophthalein and Triton X-100 were purchased from Sigma-Aldrich (Schnelldorf, Germany). Cholyl-glycylamido-fluorescein was kindly provided by Prof. Alan Hofmann (University of California, San Diego).
Materials and Methods

Chemicals
3 H-estrone-3-sulfate (E3S; 57.3 Ci/mmol) was obtained from PerkinElmer Life Sciences (Boston, MA). All other chemicals and reagents were of analytical grade and were readily available from commercial sources. CHO cells expressing OATP1B1 and OATP1B3 have been described previously (Treiber et al., 2007; Gui et al., 2008 In addition, the sigmoid inhibitory effect model was used to describe a concentration-dependent inhibitory effect by diagnostic inhibitors and the various HIV PI:
with E the accumulation of substrate in cells, E max representing the accumulation of substrate without inhibitor, E 0 the accumulation of substrate at the maximum inhibitory effect of inhibitor, E max -E 0 the maximum inhibitory effect, C the inhibitor concentration and # the shape parameter The Cheng-Prusoff equation (Cheng and Prusoff, 1973) Average estimates for K m and V max are shown in Figure 1 . CGamF exhibited an approximately 3-fold higher affinity and 5-fold higher V max for OATP1B3 compared to OATP1B1.
Effect of diagnostic inhibitors and various HIV PI on CGamF accumulation in transfected CHO cells
To 
CGamF and E3S accumulation in Caco-2 cells.
Transporter expression profiling of the Caco-2 cell populations used in our lab along with those obtained from other labs revealed that our Caco-2 cells (as well as those of most other labs tested) express high levels of OATP2B1 with absent or very low levels of the other OATP isoforms (Hayeshi et al., 2008) . Previous work has shown that OATP2B1 is predominantly responsible for the apical accumulation of E3S in Caco-2 cells (Sai et al., 2006) . In the present study, the accumulation activity of OATP2B1 using E3S as substrate showed highest in week 2 Caco-2
cultures. No accumulation of CGamF could be detected in Caco-2 cells, indicating that CGamF is most likely a very poor OATP2B1 substrate.
In order to study the inhibitory effects of HIV PI on OATP2B1 activity, E3S was used as probe substrate. Initial accumulation of E3S across the apical membrane of Caco-2 cells was determined at 2 min. Biphasic saturation kinetics were observed consistent with results from a previous study (Sai et al., 2006) . The K m values of the high-and low-affinity sites were 3.2 ± 0.3 !M and 2.9 ± 0.1 mM, and V max values were 41.1 ± 3.2 pmol/mg protein/2 min and 7.9 ± 0.5 nmol/mg protein/2 min, respectively ( Figure 5, A B) . By comparing the values of the V max /K m ratio for high-and low-affinity sites, the contribution of the high-affinity site to overall accumulation clearance at low concentration was estimated to be approximately 4 times larger than that of the low-affinity site.
Effect of OATP inhibitors and various HIV PIs on E3S accumulation in Caco-2 cells
The known OATP inhibitors, rifampicin, rifamycin SV, bromosulphophthalein and E3S itself significantly inhibited E3S accumulation in Caco-2 cells, while the specific OATP1B3 substrate digoxin had no effect. Among eight tested HIV PI, indinavir, ritonavir and saquinavir showed the most potent inhibition of E3S accumulation in Caco-2 cells (Figure 6 ).
For the four OATP inhibitors and the three most potent HIV PI, concentration-dependent inhibitory effect on the E3S accumulation in Caco-2 cells were studied in more detail (Figure 7 ). E3S accumulation in Caco-2 cells was strongly inhibited by the sulfate conjugate bromosulphophthalein (Table 2) , yielding an IC 50 value comparable with the reported value (2.9 µM) (Sai et al., 2006) .
The IC 50 /K i values for ritonavir, saquinavir and indinavir were all above the unbound plasma concentration reported for these HIV PI (see Table 1 ).
Discussion
In the present study, we first investigated the relative roles of the three different human (Ye et al., 2009 ), OATP1B3 appears to be the main sodium-independent transporter mediating human hepatic CGamF accumulation. In addition, incubations with human hepatocytes in the absence of sodium had implied NTCP supporting about 36 % of active CGamF accumulation (Ye et al., 2009) . Although the combination of in vitro data thus far obtained for CGamF (in human hepatocytes and transfected systems) do not allow to completely exclude a role for other sodium-independent mechanisms (e.g. OAT2; SLC22A7) mediating hepatic CGamF accumulation, the fact that CGamF is an amphiphilic bile acid analogue provides further evidence for the key role of OATP transporters, in casu the 1B3 isoform. Even though the relative expression level of OATP1B1 is about 2-fold higher than OATP1B3 in human liver (Hilgendorf et al., 2007) , these data support the use of CGamF as an in vitro probe substrate for sodium-independent substrate accumulation in human hepatocytes essentially mediated by OATP1B3.
Interference with OATP1B1 and 1B3-mediated CGamF accumulation was studied for the diagnostic OATP inhibitors/substrates rifampicin, digoxin and bromosulphophtalein, as well as for most HIV PI in clinical use today (Table 1 ; Figure 1 -2). The inhibition by rifampicin and bromosulphophthalein is comparable for both OATP isoforms (K i values between 0.6 and 1.6 !M), whereas upon coincubation with digoxin a much higher potency was observed for inhibiting
The observation that digoxin affected OATP1B1-mediated accumulation, albeit at a lower potency than for OATP1B3, is remarkable in light of reports classifying digoxin as a specific OATP1B3 substrate (Kullak-Ublick et al., 2001) . However, its specificity as an inhibitor was not tested in the latter study and weak interference of digoxin with OATP1B1-mediated pitavastatin accumulation has also been reported (Hirano et al., 2006) . It should be emphasized that the latter observation as well as our present data do not imply that OATP1B1 mediates digoxin transport, but only indicate some affinity of digoxin for OATP1B1. Digoxin accumulation in transfected oocytes has indeed been shown for OATP1B3 only, and not for the 1B1, 2B1 or 1A2 isoforms (Kullak-Ublick et al., 2001) . It is also noteworthy that digoxin showed relatively poor efficacy for inhibition of CGamF accumulation by both OATP1B isoforms (38% -54% max inhibition), which may indicate that multiple binding sites are involved. Using estradiol-17"-D-glucuronide as a substrate and/or inhibitor, multiple binding sites on rat Oatp1a4 have been suggested to explain activation as well as inhibition of Oatp-mediated substrate accumulation in hepatocytes (Sugiyama et al., 2002; Annaert and Brouwer, 2005) .
The concentration-dependent inhibition curves (Figure 2-3 , 2006) . In this article, the authors had speculated about the possible interference of transporters different from P-glycoprotein, such as OATPs, to explain the increased fexofenadine plasma levels. In another study, coadministration of rosuvastatin and lopinavir/ritonavir in healthy volunteers was associated with an approximately 2-and 5-fold increase in rosuvastatin steady-state AUC and C max , respectively (Kiser et al., 2008) . This increase was considered to be clinically significant requiring dose adjustment and this drug interaction was suggested to be mediated via inhibition of OATP1B1 by either ritonavir and/or lopinavir (Ayrton and Morgan, 2008) . Our in vitro data appear to support inhibition of OATP1B1 by lopinavir (rather than ritonavir) as a major mechanism here, since the unbound plasma C max level for lopinavir (0.3 !M) is only slightly lower than the K i value in our in vitro system. Figure 4A illustrates that there is a rather good correlation between inhibition potencies of both isoforms, which may indicate binding to corresponding sites on both isoforms. This is not surprising given the 80% amino acid identity between the 1B1 and 1B3 isoforms (Hagenbuch and Meier, 2003) . In the present study, the most pronounced difference between both isoforms in terms of inhibiting potency was observed for lopinavir with a 3-fold higher affinity for OATP1B1 compared to OATP1B3. For all other HIV PI, the difference was less than 2-fold. Nevertheless, considering the unbound C max concentration of lopinavir (0.3 !M), the difference in potency for lopinavir towards both isoforms may be critical with respect to the clinical relevance of drug interactions occurring at the level of OATP1B1 versus OATP1B3. In light of the above mentioned clinically relevant drug interaction between fexofenadine and lopinavir/ritonavir, inhibition of OATP1B1 by lopinavir would be the most likely mechanism. However, the relative contribution of multiple OATP isoforms to fexofenadine disposition remains controversial. Shimizu et al. (Shimizu et al., 2005) have demonstrated that OATP1B3 contributes mainly to the hepatic accumulation of fexofenadine using transporter-expressing HEK293 cells. On the other hand, Niemi et al. (Niemi et al., 2005) reported that the genetic polymorphism of OATP1B1 (T521C), which was been shown to decrease the transport clearance, increased the plasma AUC of fexofenadine. These results suggested that OATP1B1 as well as OATP1B3 are involved in the accumulation of fexofenadine into human liver. The exact relative roles of both isoforms in the drug interaction between fexofenadine and lopinavir/ritonavir remain to be elucidated.
As mentioned before, in contrast to the efficient accumulation of CGamF by the human OATP1B isoforms, no accumulation of CGamF could be detected in Caco-2 cells. As virtually exclusive expression of the 2B1 isoform among multiple members of the OATP family was shown in the Caco-2 clone used in the present study (Hayeshi and others 2008) , any role for OATP2B1 in the disposition of CGamF in human liver is highly unlikely. However, consistent with previous reports, efficient accumulation of E3S was observed across the apical membrane of Caco-2 cells, thus enabling the use of this cell line as a surrogate in vitro tool for hepatic OATP2B1-mediated substrate accumulation. Based on observed kinetics for E3S (Figure 5 ), accumulation clearance values of 1.4 and 6.4 !l/min/mg protein were obtained for the low and high capacity components, respectively. As illustrated in Figure 6 , the low affinity of digoxin for the OATP2B1 isoform was confirmed with no effect on E3S accumulation. In contrast, the less specific and/or more potent (Williams and Sinko, 1999; Hoetelmans R, 2003; Perry et al., 2005; Swainston Harrison and Scott, 2005; Marin-Niebla et al., 2007; Ruane et al., 2007; Chandwani and Shuter, 2008 ) **: due to solubility limitations, nelfinavir could only be tested up to a concentration of 20 !M 
